Development of Mitochondrial Pharmacology for Common Pathologies 2023
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 265
Special Issue Editor
Special Issue Information
Dear Colleagues,
Mitochondria are essential organelles that generate energy, as well as to regulate cell death, generate reactive oxygen species (ROS), and modulate inflammation. Damaged mitochondria and their related pathways may contribute to the development of a wide range of pathophysiological conditions. Accumulating evidence also suggests that mitochondria can also regulate specific aspects of multiple disease progression through the regulation of specific metabolic intermediates. Therefore, the maintenance of mitochondrial function and integrity provides potential therapeutic strategies for the treatment of human diseases.
Here, we focus on how mitochondria participate in disease progression and how these mechanisms may usher in a new era of mitochondria-targeted therapies. Authors are invited to submit original and review articles on preclinical and clinical findings, contributing to the understanding of mitochondrial function and quality as potential therapeutic targets, to be published in this Special Issue of Pharmaceuticals. The proposed topics should include inflammation, metabolic disorders, mitochondria-related genetic disorders, cancer, cardiovascular disease, neurodegenerative disease, and aging.
I look forward to your valuable contribution.
Dr. Nuo Sun
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
